Project Grant R01HL174545
Award Date
9/1/25
Completion Date
7/31/29
Dollars Obligated
$655K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research supports research to investigate the role of the serine-threonine kinase, serum glucocorticoid kinase 1 (SGK1), in cardiometabolic heart failure with preserved ejection fraction (CMET HFPEF). The $732,779 award to the University of Utah aims to: (1) determine the role of cardiac-specific SGK1 in regulating heart function, metabolism, and inter-organ...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $121,773 to the University of Arizona to investigate the role of the serum/glucocorticoid regulated kinase 1 (SGK1) in driving pathological cardiac hypertrophy. The research aims to determine if SGK1 is required for the development of cardiac hypertrophy and if impairing its degradation through the endoplasmic reticulum-associated degradation (ERAD)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $735,838 to the University of Arizona to conduct research on the role of hexokinase 1 (HK1) mitochondrial binding in cardiac endothelial cell function and the development of heart failure with preserved ejection fraction (HFpEF). The research aims to determine if HK1 mitochondrial dislocation leads to increased protein O-GlcNAcylation,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $699,133 in funding to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key goals are to reveal molecular insights into the actions of SGLT2 inhibitor and GLP1 agonist drugs across multiple organs, identify novel...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $507,096.00 to Wake Forest University Health Sciences to conduct research on the role of mitochondrial calcium signaling in heart failure with preserved ejection fraction (HFPEF). The key objectives are to: Characterize heart cell-specific mitochondrial calcium signaling and functions in HFPEF mouse models, 2) Evaluate the effects...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to investigate the role of cardiomyocyte glutamine synthesis in heart failure development, fibroblast activation, and cardiac metabolism. The $772,808 award to Temple University, with a project period from December 2024 to November 2028, will support research to determine if targeting cardiomyocyte glutamine synthesis can reduce the progression of heart...
The federal Project Grant award of $621,546.00 was granted on July 20, 2025 by the National Heart Lung and Blood Institute (NHLBI), under the CFDA 93.837 Cardiovascular Diseases Research program. The grant supports research focused on observing the catalytic subunit of cAMP-dependent protein kinase A (PKA-C) at the single molecule level, to understand its role in normal heart function and cardiac disease states. Key objectives include: Engineering a single-walled carbon nanotube field effect...
This Project Grant award of $473,096 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of Utah to understand the role of lactate oxidation in the mitochondria of cardiomyocytes and its impact on cardiac function in heart failure. The key objectives are to: 1) Quantify direct versus indirect mitochondrial lactate oxidation in healthy and failing hearts; 2) Determine if mitochondrial localized MCT1 is necessary...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $131,085 to The Leland Stanford Junior University to elucidate the cardiac-protective mechanisms of sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of drugs initially developed to treat diabetes. The research aims to leverage human induced pluripotent stem cell-derived cardiovascular cells, single-cell RNA sequencing, metabolomics, and protein...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...